Clinical trial
Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease
Name
YLS2020(172)
Description
To investigate the relationship among the neural respiratory drive (NRD), the sensation of the dyspnea and the effect of the bronchodilator on each stage COPD patients.
Trial arms
Trial start
2023-01-01
Estimated PCD
2023-07-01
Trial end
2023-09-01
Status
Recruiting
Treatment
compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)
inhaled compound ipratropium bromide solution (3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany)
Arms:
bronchodilators
Size
40
Primary endpoint
the change of the neural respiratory drive
20 minutes
Eligibility criteria
Inclusion Criteria:
The diagnosis of COPD was made according to the global initiative for chronic obstructive lung disease (GOLD) guideline.
-
Exclusion Criteria:
(1) Malignancy （2）Severe cardiovascular diseases （3）Neuromuscular and chest wall deformity (4) Cardiovascular instability (hypotension, arrhythmias, myocardial infarction) (5) Change in mental status; uncooperative patients (6) Extreme obesity （7）renal failure and severe blood electrolyte disturbances (8) Asthma-
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'the responds of the neural respiratory drive of the chronic obstructive pulmonary disease patients after inhaling bronchodilator(3mg salbutamol and 500μg ipratropium, Boehringer Ingelheim Limited, Germany).', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}
Updated at
2023-03-28
1 organization
1 product
1 indication
Product
Ipratropium BromideIndication
Chronic Obstructive Pulmonary Disease